Company Profile & Origins
GlaxoSmithKline (GSK) is one of the world’s oldest biopharmaceutical companies. Its origin dates back to 1715, when a London apothecary started producing medicines under the name Plough Court Pharmacy. Over the centuries, through mergers with Burroughs Wellcome, Beecham, SmithKline, and Glaxo, the company evolved into GSK plc in 2000. Its headquarters is located in Brentford, London, United Kingdom.
Today, GSK operates in more than 100 countries. The company focuses on medicines, vaccines, consumer health products and is recognized globally for pioneering vaccine research, development, and production. GSK continues to play a key role in preventing infectious diseases for people of all ages.
Research, Innovation & Technology
GSK has been leading vaccine innovation for more than 100 years. Today, it has over 20 vaccines in use worldwide and its research pipeline also targets future health threats.
Key innovations include:
Adjuvant Systems (AS04, AS01): Special GSK technology that strengthens immune response, used in vaccines such as Cervarix® (HPV) and Shingrix® (Shingles).
mRNA and recombinant protein platforms: GSK collaborates globally to develop next-generation vaccines that are faster to produce and adaptable to new virus variants.
Advanced manufacturing sites: Facilities in Belgium, Italy, and Singapore ensure strict quality control and a steady vaccine supply nationwide.
Through these technologies, GSK delivers safe, reliable, and effective vaccines to communities worldwide.
Vaccine Portfolio
GSK offers vaccines for infants, children, adolescents, adults, and seniors. Its range covers routine immunizations and workplace health programs.
Key Vaccines:
Influenza: Fluarix® Tetra – Provides broad seasonal flu protection.
Hepatitis A & B: Havrix®, Engerix-B®, and Twinrix® (combined Hep A & B).
HPV: Cervarix® – Protects against HPV types 16 and 18 linked to cervical cancer.
Meningococcal: Menveo® – Protects against serogroups A, C, Y, and W-135.
Tetanus, Diphtheria & Pertussis: Boostrix® – Adult and adolescent booster.
Shingles: Shingrix® – Recombinant zoster vaccine giving over 90% protection against shingles and complications.
GSK’s portfolio supports corporate vaccination programs, enabling companies to protect employees from flu, hepatitis, HPV, meningitis, and Tdap.
Medical Breakthroughs & Global Impact
GSK has achieved several important milestones:
Among the first to develop Hepatitis and HPV vaccines for cancer prevention.
Innovator of adjuvant technology, making Shingrix® the most effective shingles vaccine globally.
Partners with WHO and Gavi to improve vaccine access in developing countries.
Developed Mosquirix® (RTS,S), the first approved malaria vaccine, saving countless lives in sub-Saharan Africa.
These breakthroughs demonstrate GSK’s commitment to improving global health and protecting communities.
Presence in the Philippines
GSK has been active in the Philippines for over 50 years, with its Philippine headquarters located in Taguig City. The company collaborates with hospitals, physicians, and corporate clients to ensure reliable access to vaccine.
GSK’s vaccines—including influenza, hepatitis, and Tdap are widely used in corporate programs and public health initiatives. Additionally, GSK supports professional training and awareness programs to promote safe and effective immunization delivery.
Shared Commitment to Prevention
Affinity Vaccines partners with GSK to provide safe, trusted vaccines to workplaces and institutions. By combining GSK’s global expertise with Affinity’s corporate health programs, companies can effectively protect their employees and their families. Therefore, organizations can build healthier, safer workplaces by using GSK vaccines.
Protect your workforce with vaccines from GSK and other global leaders.
Contact vaccines@affinity.com.ph to plan your company’s immunization program today. 📩 Request for a Corporate Vaccination Proposal